Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine in the U.S. in Nearly 20 Years for Indicated Patients Awaiting a New Option ––...
Esperion announces commercial availability of Nexletol tablet in the U.S. ESPR
09:40am, Monday, 30'th Mar 2020
Esperion announces commercial availability of Nexletol tablet in the U.S. ESPR
Zacks Investment Research Upgrades Esperion Therapeutics (NASDAQ:ESPR) to Buy
07:00am, Monday, 30'th Mar 2020
Esperion Therapeutics (NASDAQ:ESPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, Zacks.com reports. The
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced results from two pooled analyses from four Phase 3 clinical trials for bempedoic acid and separate results from a Phase 2 s
Esperion Reports Commercial Availability Of NEXLETOL Tablet
12:00am, Monday, 30'th Mar 2020Esperion Therapeutics (NASDAQ:ESPR) Stock Price Down 5.6%
09:47am, Sunday, 29'th Mar 2020
Esperion Therapeutics Inc (NASDAQ:ESPR)’s stock price traded down 5.6% during mid-day trading on Friday . The company traded as low as $35.24 and last traded at $35.29, 525,267 shares changed hands
Esperion Therapeutics (ESPR) Down 32.5% Since Last Earnings Report: Can It Rebound?
03:30pm, Saturday, 28'th Mar 2020
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion Therapeutics (ESPR) Down 32.5% Since Last Earnings Report: Can It Rebound?
03:30pm, Saturday, 28'th Mar 2020
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion announces data presentations of NEXLETOL, NEXLIZET Tablet ESPR
02:20pm, Saturday, 28'th Mar 2020
Esperion announces data presentations of NEXLETOL, NEXLIZET Tablet ESPR
Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC)
01:30pm, Saturday, 28'th Mar 2020
ANN ARBOR, Mich., March 28, 2020 -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2.
Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC)
01:30pm, Saturday, 28'th Mar 2020
ANN ARBOR, Mich., March 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of...
Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the ...
12:00am, Saturday, 28'th Mar 2020Marshall Wace North America L.P. Buys New Position in Esperion Therapeutics Inc (NASDAQ:ESPR)
11:00am, Thursday, 26'th Mar 2020
Marshall Wace North America L.P. bought a new stake in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Co
Esperion Therapeutics (NASDAQ:ESPR) Shares Up 5.7%
08:26am, Thursday, 26'th Mar 2020
Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) shot up 5.7% on Tuesday . The company traded as high as $39.39 and last traded at $37.77, 580,423 shares traded hands during mid-day trading. A declin
Ancora Advisors LLC Buys New Holdings in Esperion Therapeutics Inc (NASDAQ:ESPR)
09:08am, Wednesday, 25'th Mar 2020
Ancora Advisors LLC bought a new stake in Esperion Therapeutics Inc (NASDAQ:ESPR) in the fourth quarter, Holdings Channel reports. The institutional investor bought 2,250 shares of the biopharmaceutic
